

Walter Maetzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5241387/publications.pdf>

Version: 2024-02-01

297
papers

16,760
citations

19657

61
h-index

23533

111
g-index

324
all docs

324
docs citations

324
times ranked

22190
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	21.4	1,685
2	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	21.4	502
3	The release and trans-synaptic transmission of Tau via exosomes. <i>Molecular Neurodegeneration</i> , 2017, 12, 5.	10.8	475
4	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	3.9	464
5	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	9.0	374
6	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.8	344
7	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	6.2	333
8	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , 2016, 91, 56-66.	8.1	289
9	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1628-1637.	3.9	287
10	Progression of Parkinson's disease in the clinical phase: potential markers. <i>Lancet Neurology</i> , The, 2009, 8, 1158-1171.	10.2	261
11	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 470-478.	3.9	251
12	BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. <i>Journal of Psychiatric Research</i> , 2007, 41, 387-394.	3.1	249
13	A Pan-European Study of the C9orf72 Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
14	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. <i>Molecular Psychiatry</i> , 2015, 20, 647-656.	7.9	235
15	GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , 2015, 30, 407-411.	3.9	214
16	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019, 34, 657-663.	3.9	213
17	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology</i> , The, 2020, 19, 462-470.	10.2	181
18	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	178

#	ARTICLE	IF	CITATIONS
19	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. <i>Neurobiology of Disease</i> , 2009, 34, 107-112.	4.4	177
20	Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e73094.	2.5	176
21	S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF- α pathway. <i>Brain</i> , 2012, 135, 3336-3347.	7.6	159
22	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016, 13, 24.	4.6	155
23	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.5	146
24	Health-Related Quality of Life in patients with Parkinson's disease – A systematic review based on the ICF model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 61, 26-34.	6.1	144
25	Gait analysis with wearables predicts conversion to Parkinson disease. <i>Annals of Neurology</i> , 2019, 86, 357-367.	5.3	137
26	[11C]PIB binding in Parkinson's disease dementia. <i>NeuroImage</i> , 2008, 39, 1027-1033.	4.2	133
27	A clinical view on the development of technology-based tools in managing Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1263-1271.	3.9	131
28	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. <i>Movement Disorders</i> , 2014, 29, 479-487.	3.9	130
29	Comparison of acceleration signals of simulated and real-world backward falls. <i>Medical Engineering and Physics</i> , 2011, 33, 368-373.	1.7	127
30	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	10.2	126
31	Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. <i>Acta Diabetologica</i> , 2014, 51, 679-681.	2.5	123
32	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. <i>Movement Disorders</i> , 2016, 31, 1283-1292.	3.9	119
33	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 102-108.	3.3	113
34	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , 2007, 25, 473-482.	4.4	111
35	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.8	104
36	Prodromal features for Parkinson's disease – baseline data from the TREND study. <i>European Journal of Neurology</i> , 2014, 21, 766-772.	3.3	99

#	ARTICLE	IF	CITATIONS
37	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , 2018, 9, 17455-17465.	1.8	94
38	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	7.7	93
39	Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 73-77.	2.2	92
40	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1401-1408.	3.9	91
41	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	2.5	87
42	Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. <i>Neurobiology of Aging</i> , 2012, 33, 2949.e13-2949.e17.	3.1	86
43	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. <i>JAMA Oncology</i> , 2020, 6, 714.	7.1	84
44	The Brain Response to Peripheral Insulin Declines with Age: A Contribution of the Blood-Brain Barrier?. <i>PLoS ONE</i> , 2015, 10, e0126804.	2.5	80
45	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 457.	2.4	79
46	Impaired Trunk Stability in Individuals at High Risk for Parkinson's Disease. <i>PLoS ONE</i> , 2012, 7, e32240.	2.5	79
47	Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly – Baseline Results from the TREND Study. <i>PLoS ONE</i> , 2011, 6, e27831.	2.5	78
48	Motor signs in the prodromal phase of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 627-633.	3.9	78
49	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	78
50	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , 2016, 91, 59-68.	4.4	78
51	Ageing-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. <i>Neurobiology of Aging</i> , 2013, 34, 439-450.	3.1	77
52	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017, 32, 1025-1034.	3.9	75
53	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 51.	3.4	74
54	A combined miRNA-piRNA signature to detect Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 250.	4.8	74

#	ARTICLE	IF	CITATIONS
55	Glial Cell-Line Derived Neurotrophic Factor (GDNF) Concentrations in Cerebrospinal Fluid and Serum of Patients with Early Alzheimer's Disease and Normal Controls. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 331-337.	2.6	72
56	Intra-Rater, Inter-Rater and Test-Retest Reliability of an Instrumented Timed Up and Go (iTUG) Test in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0151881.	2.5	72
57	Quantitative home-based assessment of Parkinson's symptoms: The SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , 2015, 15, 89.	1.8	71
58	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012, 119, 39-52.	2.8	68
59	The FARSEEING real-world fall repository: a large-scale collaborative database to collect and share sensor signals from real-world falls. <i>European Review of Aging and Physical Activity</i> , 2016, 13, 8.	2.9	67
60	Alterations in Blood Monocyte Functions in Parkinson's Disease. <i>Movement Disorders</i> , 2019, 34, 1711-1721.	3.9	67
61	Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs. <i>Genomics, Proteomics and Bioinformatics</i> , 2019, 17, 430-440.	6.9	67
62	Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101549.	7.1	66
63	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , 2011, 26, 2335-2342.	3.9	65
64	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1270-1272.	1.9	65
65	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S53-S56.	2.2	63
66	Highly potent soluble amyloid- β seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014, 137, 2909-2915.	7.6	61
67	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. <i>Genetics in Medicine</i> , 2018, 20, 240-249.	2.4	60
68	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , 2016, 13, 122.	7.2	57
69	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 427.	3.3	56
70	How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review. <i>Npj Parkinson's Disease</i> , 2021, 7, 25.	5.3	56
71	Technical validation of real-world monitoring of gait: a multicentric observational study. <i>BMJ Open</i> , 2021, 11, e050785.	1.9	56
72	Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 171-179.	2.6	55

#	ARTICLE	IF	CITATIONS
73	Are Hypometric Anticipatory Postural Adjustments Contributing to Freezing of Gait in Parkinson's Disease?. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 36.	3.4	54
74	Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. <i>Npj Digital Medicine</i> , 2021, 4, 149.	10.9	54
75	Validating Alzheimer's disease micro RNAs using next-generation sequencing. <i>Alzheimer's and Dementia</i> , 2016, 12, 565-576.	0.8	53
76	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , 2016, 31, 593-596.	3.9	51
77	Vorschlag für ein Mehrphasensturzmodell auf der Basis von Sturzdokumentationen mit am Körper getragenen Sensoren. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2012, 45, 707-715.	1.8	50
78	Emerging therapies for gait disability and balance impairment: Promises and pitfalls. <i>Movement Disorders</i> , 2013, 28, 1576-1586.	3.9	50
79	Technical and clinical view on ambulatory assessment in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 139-147.	2.1	49
80	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 226.	2.0	47
81	α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2508-2518.	3.9	47
82	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration" [¹⁸ F]FDG-PET. <i>Movement Disorders</i> , 2009, 24, 1504-1511.	3.9	46
83	Common diseases alter the physiological age-related blood microRNA profile. <i>Nature Communications</i> , 2020, 11, 5958.	12.8	46
84	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010, 25, 1464-1469.	3.9	45
85	Serum Insulinlike Growth Factor 1 as Possible Marker for Risk and Early Diagnosis of Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 925.	4.5	45
86	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. <i>Frontiers in Neurology</i> , 2018, 9, 500.	2.4	45
87	Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 22.	3.4	45
88	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	2.8	45
89	Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity. <i>Npj Parkinson's Disease</i> , 2021, 7, 24.	5.3	44
90	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , 2011, 26, 176-181.	3.9	43

#	ARTICLE	IF	CITATIONS
91	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 419-425.	2.8	43
92	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
93	Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson's Disease in the Home or a Home-like Environment. <i>Journal of Parkinson's Disease</i> , 2020, 10, 429-454.	2.8	43
94	Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis. <i>Frontiers in Neurology</i> , 2018, 9, 668.	2.4	42
95	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001741.	2.8	42
96	Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes. <i>Sensors</i> , 2020, 20, 5920.	3.8	42
97	Wearables for gait and balance assessment in the neurological ward - study design and first results of a prospective cross-sectional feasibility study with 384 inpatients. <i>BMC Neurology</i> , 2018, 18, 114.	1.8	41
98	Less Is More – Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 435.	3.4	41
99	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , 2021, 90, E1-E12.	5.3	41
100	Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. <i>Neurobiology of Aging</i> , 2011, 32, 1599-1606.	3.1	40
101	Serum and Cerebrospinal Fluid Uric Acid Levels in Lewy Body Disorders: Associations with Disease Occurrence and Amyloid- β Pathway. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 119-126.	2.6	40
102	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 279-287.	2.8	40
103	The Mutation Matters: CSF Profiles of GCa6, Sphingolipids, β -Synuclein in PD > GBA. <i>Movement Disorders</i> , 2021, 36, 1216-1228.	3.9	40
104	Associations between Early Markers of Parkinson's Disease and Sarcopenia. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 53.	3.4	39
105	What is Functional Mobility Applied to Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2018, 8, 121-130.	2.8	39
106	Validation of IMU-based gait event detection during curved walking and turning in older adults and Parkinson's Disease patients. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021, 18, 28.	4.6	39
107	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , 2016, 37, 208.e11-208.e17.	3.1	38
108	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1245-1248.	3.9	37

#	ARTICLE	IF	CITATIONS
109	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0151997.	2.5	37
110	Improvement of balance after audio-biofeedback. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2010, 43, 224-228.	1.8	36
111	Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease. <i>Current Alzheimer Research</i> , 2010, 7, 409-414.	1.4	36
112	SNCA: Major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1217-1221.	3.9	36
113	Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson's Disease Patients and Controls. <i>PLoS ONE</i> , 2014, 9, e88604.	2.5	36
114	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
115	Continuous leg dyskinesia assessment in Parkinson's disease – clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 41-46.	2.2	36
116	Decreased α -Synuclein Serum Levels in Patients with Lewy Body Dementia Compared to Alzheimer's Disease Patients and Control Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 413-416.	1.5	35
117	Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 362-370.	2.1	35
118	The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 74-81.	2.2	35
119	Effect of Fear of Falling on Turning Performance in Parkinson's Disease in the Lab and at Home. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 78.	3.4	35
120	Soluble α CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 963-976.	3.9	35
121	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015, 36, 1072-1074.	3.1	34
122	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 32-37.	1.9	34
123	Risk for Femoral Fractures in Parkinson's Disease Patients with and without Severe Functional Impairment. <i>PLoS ONE</i> , 2014, 9, e97073.	2.5	33
124	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 147.	3.4	33
125	How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, S41-S45.	2.8	33
126	The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 937-942.	2.6	32

#	ARTICLE	IF	CITATIONS
127	Parkinson's Disease: <i>Glucocerebrosidase 1</i> Mutation Severity Is Associated with CSF Alphaâ€Synuclein Profiles. <i>Movement Disorders</i> , 2020, 35, 495-499.	3.9	32
128	Influence of Different Cut-Off Values on the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.	1.1	31
129	Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	2.0	31
130	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsyâ€parkinsonism. <i>Movement Disorders</i> , 2012, 27, 151-155.	3.9	31
131	Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. , 2015, 11, 465-474.		31
132	Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. <i>PLoS ONE</i> , 2016, 11, e0150552.	2.5	31
133	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , 2021, 36, 76-82.	3.9	31
134	Altered Serum IgG Levels to Î±-Synuclein in Dementia with Lewy Bodies and Alzheimerâ€™s Disease. <i>PLoS ONE</i> , 2013, 8, e64649.	2.5	31
135	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. <i>Current Alzheimer Research</i> , 2016, 13, 654-662.	1.4	31
136	Ectopic parvalbumin expression in mouse forebrain neurons increases excitotoxic injury provoked by ibotenic acid injection into the striatum. <i>Experimental Neurology</i> , 2004, 186, 78-88.	4.1	30
137	In vivo comparison of Richardsonâ€™s syndrome and progressive supranuclear palsy-parkinsonism. <i>Journal of Neural Transmission</i> , 2011, 118, 1191-1197.	2.8	30
138	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , 2020, 3, 116-132.	4.4	30
139	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747.	3.9	29
140	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinsonâ€™s disease diagnosis. <i>PLoS ONE</i> , 2018, 13, e0206536.	2.5	29
141	Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. <i>BMJ Open</i> , 2020, 10, e038704.	1.9	29
142	The detection of age groups by dynamic gait outcomes using machine learning approaches. <i>Scientific Reports</i> , 2020, 10, 4426.	3.3	29
143	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , 2021, 96, e399-e411.	1.1	29
144	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinsonâ€™s Disease and Lewy Body Dementia. <i>PLoS ONE</i> , 2016, 11, e0149349.	2.5	29

#	ARTICLE	IF	CITATIONS
145	No association of <i>GBA</i> mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013, 20, e61-2.	3.3	28
146	Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. <i>Frontiers in Neurology</i> , 2018, 9, 652.	2.4	28
147	Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. <i>Journal of Parkinson's Disease</i> , 2015, 5, 187-196.	2.8	27
148	Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 59.	2.0	27
149	Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 154.	3.4	26
150	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 135.	2.4	26
151	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , 2018, 165, 88-93.	1.4	26
152	Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 1040-1046.	3.9	25
153	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 764-767.	1.9	25
154	Body-worn sensors-the brave new world of clinical measurement?. <i>Movement Disorders</i> , 2015, 30, 1203-1205.	3.9	25
155	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 423-432.	2.8	25
156	Mild Parkinsonian Signs in the Elderly " Is There an Association with PD? Crosssectional Findings in 992 Individuals. <i>PLoS ONE</i> , 2014, 9, e92878.	2.5	25
157	Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson's Disease: Sources of (Error) Variance in Biomarker Assays. <i>PLoS ONE</i> , 2014, 9, e114566.	2.5	24
158	Dementia with lewy bodies: <i>GBA1</i> mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , 2019, 34, 1069-1073.	3.9	24
159	Gait Analysis with Wearables Can Accurately Classify Fallers from Non-Fallers: A Step toward Better Management of Neurological Disorders. <i>Sensors</i> , 2020, 20, 6992.	3.8	24
160	Short-term physical exercise impacts on the human holobiont obtained by a randomised intervention study. <i>BMC Microbiology</i> , 2021, 21, 162.	3.3	24
161	GABAB receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. <i>Neuroscience Letters</i> , 2006, 395, 118-123.	2.1	23
162	Nepriylsin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid- β 42 Levels in Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 933-938.	2.6	23

#	ARTICLE	IF	CITATIONS
163	Digitomotography in Parkinson's Disease: A Cross-Sectional and Longitudinal Study. PLoS ONE, 2015, 10, e0123914.	2.5	23
164	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology, 2015, 45, 282-297.	2.3	23
165	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. Frontiers in Aging Neuroscience, 2016, 8, 4.	3.4	23
166	Is the Assessment of 5 Meters of Gait with a Single Body-Fixed-Sensor Enough to Recognize Idiopathic Parkinson's Disease-Associated Gait?. Annals of Biomedical Engineering, 2017, 45, 1266-1278.	2.5	23
167	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in <i>GRN</i>-Negative Frontotemporal Dementia. Neurodegenerative Diseases, 2017, 17, 83-88.	1.4	23
168	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	6.4	23
169	Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia. PLoS ONE, 2012, 7, e48042.	2.5	23
170	Progressive Secondary Neurodegeneration and Microcalcification Co-Occur in Osteopontin-Deficient Mice. American Journal of Pathology, 2010, 177, 829-839.	3.8	22
171	Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid A deposition. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1060-1062.	1.9	22
172	Development of a standard fall data format for signals from body-worn sensors. Zeitschrift Fur Gerontologie Und Geriatrie, 2013, 46, 720-726.	1.8	22
173	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. Movement Disorders, 2020, 35, 1233-1238.	3.9	22
174	Microcalcification after excitotoxicity is enhanced in transgenic mice expressing parvalbumin in all neurones, may commence in neuronal mitochondria and undergoes structural modifications over time. Neuropathology and Applied Neurobiology, 2009, 35, 165-177.	3.2	21
175	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. PLoS ONE, 2015, 10, e0138863.	2.5	21
176	Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: The Progression Markers in the Premotor Phase Study. Neuroepidemiology, 2013, 41, 174-182.	2.3	20
177	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism and Related Disorders, 2015, 21, 1427-1434.	2.2	20
178	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. Movement Disorders, 2016, 31, 1337-1338.	3.9	20
179	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. Neurotherapeutics, 2020, 17, 1736-1746.	4.4	20
180	Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Movement Disorders, 2012, 27, 288-293.	3.9	19

#	ARTICLE	IF	CITATIONS
181	Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 367-375.	2.6	19
182	Cognitive impairment in Glucocerebrosidase (GBA)â€associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017, 32, 1780-1783.	3.9	19
183	Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 75.	3.4	19
184	No relevant association of kinematic gait parameters with Health-related Quality of Life in Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2017, 12, e0176816.	2.5	19
185	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	2.4	19
186	Classification of Neurological Patients to Identify Fallers Based on Spatial-Temporal Gait Characteristics Measured by a Wearable Device. <i>Sensors</i> , 2020, 20, 4098.	3.8	19
187	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment â€ the ComOn-study. <i>BMC Geriatrics</i> , 2020, 20, 45.	2.7	19
188	Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. <i>Gerontology</i> , 2020, 66, 409-415.	2.8	19
189	Instrumented Functional Reach Test Differentiates Individuals at High Risk for Parkinson's Disease from Controls. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 286.	3.4	18
190	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 530.	0.8	18
191	Association of Plasma AÎ²40 Peptides, But Not AÎ²42, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 161-169.	2.6	18
192	Postural transitions detection and characterization in healthy and patient populations using a single waist sensor. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 70.	4.6	18
193	A Deep Learning Approach for Gait Event Detection from a Single Shank-Worn IMU: Validation in Healthy and Neurological Cohorts. <i>Sensors</i> , 2022, 22, 3859.	3.8	18
194	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 413-416.	2.2	17
195	Advances in sensor and wearable technologies for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1257-1257.	3.9	17
196	Assessment of cognitiveâ€driven activity of daily living impairment in nonâ€demented Parkinson's patients. <i>Journal of Neuropsychology</i> , 2020, 14, 69-84.	1.4	17
197	Quantification of Arm Swing during Walking in Healthy Adults and Parkinsonâ€™s Disease Patients: Wearable Sensor-Based Algorithm Development and Validation. <i>Sensors</i> , 2020, 20, 5963.	3.8	17
198	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. <i>Journal of Neural Transmission</i> , 2009, 116, 599-605.	2.8	16

#	ARTICLE	IF	CITATIONS
199	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 121.	3.4	16
200	Arm swing asymmetry in overground walking. <i>Scientific Reports</i> , 2018, 8, 12803.	3.3	16
201	Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study. <i>Cerebellum</i> , 2019, 18, 340-348.	2.5	16
202	Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. <i>Sensors</i> , 2021, 21, 5833.	3.8	16
203	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. <i>Neurobiology of Disease</i> , 2009, 35, 296-301.	4.4	15
204	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , 2015, 15, 192.	1.8	15
205	Reasons for mild parkinsonian signs – Which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 126-130.	2.2	15
206	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. <i>Journal of Neuroimmunology</i> , 2016, 290, 60-65.	2.3	15
207	Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 646.	2.4	15
208	Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measures using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson's disease. <i>BMJ Open</i> , 2020, 10, e041303.	1.9	15
209	A Neurodegenerative Vascular Burden Index and the Impact on Cognition. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 161.	3.4	14
210	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 281-290.	2.8	14
211	Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 235.	3.4	14
212	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	6.2	14
213	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). <i>Neurobiology of Aging</i> , 2018, 70, 242-246.	3.1	14
214	Parkinson's disease: evolution of cognitive impairment and CSF A β ₄₂ profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 165-170.	1.9	14
215	Reliability of IMU-Derived Static Balance Parameters in Neurological Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3644.	2.6	14
216	Arm swing responsiveness to dopaminergic medication in Parkinson's disease depends on task complexity. <i>Npj Parkinson's Disease</i> , 2021, 7, 89.	5.3	14

#	ARTICLE	IF	CITATIONS
217	Using multi-dimensional dynamic time warping for TUG test instrumentation with inertial sensors. , 2012, , .		13
218	A "bird's eye" view on the current status and potential benefits of blood biomarkers for Parkinson's disease. Biomarkers in Medicine, 2014, 8, 225-227.	1.4	13
219	Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study. Movement Disorders, 2017, 32, 1254-1256.	3.9	13
220	SNPs in A β clearance proteins. Neurology, 2017, 89, 2335-2340.	1.1	13
221	Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease. Sensors, 2021, 21, 3974.	3.8	13
222	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis. Frontiers in Aging Neuroscience, 2022, 14, 783996.	3.4	13
223	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
224	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 213.	3.4	12
225	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. European Journal of Neurology, 2021, 28, 1557-1565.	3.3	12
226	Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. Dementia and Geriatric Cognitive Disorders, 2007, 23, 351-367.	1.5	11
227	Freezing of Swallowing. Movement Disorders Clinical Practice, 2016, 3, 490-493.	1.5	11
228	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. Ultraschall in Der Medizin, 2017, 38, 294-300.	1.5	11
229	Changing views after 200 years of Parkinson disease. Nature Reviews Neurology, 2018, 14, 70-72.	10.1	11
230	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 55.	3.4	11
231	Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease. Journal of Neurology, 2021, 268, 2506-2514.	3.6	11
232	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. Cerebellum, 2021, 20, 662-666.	2.5	11
233	Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait. Parkinsonism and Related Disorders, 2021, 84, 8-14.	2.2	11
234	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. Annals of Clinical and Translational Neurology, 2021, 8, 1122-1131.	3.7	11

#	ARTICLE	IF	CITATIONS
235	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 317-323.	1.4	11
236	Peripheral neuropathy in Parkinson's disease: prevalence and functional impact on gait and balance. <i>Brain</i> , 2023, 146, 225-236.	7.6	11
237	Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes. <i>Neurodegenerative Diseases</i> , 2017, 17, 135-144.	1.4	10
238	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1349-1353.	3.9	10
239	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , 2019, 10, 523-530.	1.2	10
240	Functional movement disorders in neurogeriatric inpatients. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019, 52, 324-329.	1.8	10
241	Step Length Is a Promising Progression Marker in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 2292.	3.8	10
242	Neurogeriatrics' vision for improved care and research for geriatric patients with predominating neurological disabilities. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2020, 53, 340-346.	1.8	10
243	Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia. <i>PLoS ONE</i> , 2013, 8, e82902.	2.5	10
244	The Use of Virtual and Immersive Technology in Creating Personalized Multisensory Spaces for People Living With Dementia (SENSE-GARDEN): Protocol for a Multisite Before-After Trial. <i>JMIR Research Protocols</i> , 2019, 8, e14096.	1.0	10
245	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology. <i>Journal of the Neurological Sciences</i> , 2022, 435, 120197.	0.6	10
246	Lowered Serum Amyloid- β 1-42 Autoantibodies in Individuals with Lifetime Depression. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 95-100.	2.6	9
247	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , 2021, 96, e904-e915.	1.1	9
248	Wearable Health Technology to Quantify the Functional Impact of Peripheral Neuropathy on Mobility in Parkinson's Disease: A Systematic Review. <i>Sensors</i> , 2020, 20, 6627.	3.8	9
249	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 β -synuclein antibody. <i>Acta Neuropathologica</i> , 2014, 128, 893-5.	7.7	8
250	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. <i>Journal of Neural Transmission</i> , 2015, 122, 1167-1174.	2.8	8
251	Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2018, 9, 1084.	2.4	8
252	The Power of Musification: Sensor-Based Music Feedback Improves Arm Swing in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1240-1247.	1.5	8

#	ARTICLE	IF	CITATIONS
253	Comment: Why do nondopaminergic features in Parkinson disease matter?. <i>Neurology</i> , 2014, 82, 417-417.	1.1	7
254	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinsonâ€™s disease patients. <i>Journal of Neurology</i> , 2018, 265, 1976-1984.	3.6	7
255	Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinsonâ€™s disease patients.. <i>Neuropsychology</i> , 2020, 34, 447-455.	1.3	7
256	Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 722830.	3.4	7
257	Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?. <i>Age and Ageing</i> , 2022, 51, .	1.6	7
258	Longitudinal Changes of Nerve Conduction Velocity, Distal Motor Latency, Compound Motor Action Potential Duration, and Skin Temperature During Prolonged Exposure to Cold in a Climate Chamber. <i>International Journal of Neuroscience</i> , 2012, 122, 528-531.	1.6	6
259	Dementia with Lewy bodies. <i>NeuroReport</i> , 2017, 28, 1061-1065.	1.2	6
260	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 455-462.	2.8	6
261	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2019, 10, 372.	2.4	6
262	Digital assessment at home â€” mPower against Parkinson disease. <i>Nature Reviews Neurology</i> , 2021, 17, 661-662.	10.1	6
263	Reliability of IMU-Derived Temporal Gait Parameters in Neurological Diseases. <i>Sensors</i> , 2022, 22, 2304.	3.8	6
264	Quantitative motor assessment of dyskinesias in Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1271-1278.	2.8	5
265	Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 271.	3.4	5
266	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
267	Post-Cueing Deficits with Maintained Cueing Benefits in Patients with Parkinson's Disease Dementia. <i>Frontiers in Neurology</i> , 2014, 5, 236.	2.4	4
268	Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 37-43.	2.2	4
269	Everyday Function in Alzheimerâ€™s and Parkinsonâ€™s Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 197-209.	2.6	4
270	A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 49.	5.3	4

#	ARTICLE	IF	CITATIONS
271	Private variants in PRKN are associated with late-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 24-26.	2.2	4
272	Increased functional connectivity in a population at risk of developing Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 1-6.	2.2	4
273	Active Magnetoelectric Motion Sensing: Examining Performance Metrics with an Experimental Setup. <i>Sensors</i> , 2021, 21, 8000.	3.8	4
274	Therapeutic climbing in Parkinson's disease: Differences in self-reported health and well-being, feasibility and clinical changes. <i>Physiotherapy Theory and Practice</i> , 2023, 39, 1163-1177.	1.3	4
275	Postural Sway in Parkinson's Disease and Multiple Sclerosis Patients During Tasks With Different Complexity. <i>Frontiers in Neurology</i> , 2022, 13, 857406.	2.4	4
276	Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs. <i>Movement Disorders</i> , 2019, 34, 144-146.	3.9	3
277	Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 250.	3.4	3
278	Age-related deterioration of performance and increase of cortex activity comparing time- versus item-controlled fNIRS measurement. <i>Scientific Reports</i> , 2021, 11, 6766.	3.3	3
279	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	1.1	2
280	Sarkopenie. , 2019, , 69-84.		2
281	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , 2021, 12, 757748.	2.4	2
282	Functional Movement Disorder in Older Adults. <i>Current Clinical Neurology</i> , 2022, , 197-203.	0.2	2
283	Additive Effect of Dopaminergic Medication on Gait Under Single and Dual-Tasking Is Greater Than of Deep Brain Stimulation in Advanced Parkinson Disease With Long-duration Deep Brain Stimulation. <i>Neuromodulation</i> , 2022, , .	0.8	2
284	Fear of Falling Does Not Influence Dual-Task Gait Costs in People with Parkinson's Disease: A Cross-Sectional Study. <i>Sensors</i> , 2022, 22, 2029.	3.8	2
285	Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, , 1.	2.8	2
286	Reply: Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease. <i>Brain</i> , 0, , .	7.6	2
287	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 260.	3.4	1
288	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. <i>Frontiers in Neurology</i> , 2019, 10, 833.	2.4	1

#	ARTICLE	IF	CITATIONS
289	Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observation. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 83-84.	2.2	1
290	Reply: Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , 2012, 27, 1584-1585.	3.9	0
291	Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-2.	2.0	0
292	Progressive Supranuclear Palsy and Dementia. , 2015, , 147-157.		0
293	Reply to "Quantitative Motor Functioning in Prodromal Parkinson Disease". <i>Annals of Neurology</i> , 2019, 86, 981-982.	5.3	0
294	The Role of Mobility Endpoints in Marketing Authorisation of Drugs: What Gets the EMA Moving?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
295	Gait and turning alterations in idiopathic REM sleep behavioral disorder and early Parkinson's disease: A cross-sectional study with mobile health technology. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119499.	0.6	0
296	Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF). , 2019, , 7-22.		0
297	Static Balance and Chair-Rise Performance in Neurogeriatric Patients: Promising Short Physical Performance Battery-Derived Predictors of Fear of Falling. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0